M Tonello1,2, G Ortega-Perez3, O Alonso-Casado3, P Torres-Mesa3,4, G Guiñez3,5, S Gonzalez-Moreno3. 1. Peritoneal Surface Oncology Program, Department of Surgical Oncology, MD Anderson Cancer Center, Madrid, Spain. marco.tonello1@gmail.com. 2. University of Padua, Padua, Italy. marco.tonello1@gmail.com. 3. Peritoneal Surface Oncology Program, Department of Surgical Oncology, MD Anderson Cancer Center, Madrid, Spain. 4. Gastrolife SAS, Bogotá, Colombia. 5. Clinica Alemana, Santiago de Chile, Chile.
Abstract
PURPOSE: Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) has poor survival. Multi-modal treatment including systemic chemotherapy, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) can be used in selected patients with curative intent. The majority published works consider PC of CRC origin as a homogenous disease. Aim of this study is to stress the different biological behaviors and survival of PC according to colonic or rectal origin. METHODS: Data of CRS and HIPEC procedures for PC of CRC origin performed at MD Anderson Cancer Center-Madrid (Spain) have been collected, dividing patients into two groups according to colonic or rectal PC. Clinical, operatory, and postoperatory variables of the two groups have been analyzed to compare survival-related rates and PC origin. RESULTS: In the years 2004-2015, 114 procedures of CRS followed by HIPEC for peritoneal metastasis of different origin have been performed; of these, 36 procedures were for colorectal PC (31 patients in colonic and 5 in rectal group). Two groups are homogenous after analysis of clinical, operatory, and follow-up data. Median survival (OS) is significantly higher in colonic compared to rectal group (47.83 vs. 22.0 months, p 0.008). 3- and 5-year survival rate is 74 and 50% in colonic group vs. 20 and 0% in rectal group. CONCLUSION: Rectal origin PC has a more aggressive behavior compared to colonic origin, reflecting in a worst prognosis of patients affected by rectal origin PC. According to our data and literature, indications of multi-modal treatment including CRS and HIPEC should be more restrictive for rectal cancer PC. Authors should differentiate colonic and rectal origin of PC when reporting cases in the literature.
PURPOSE:Peritoneal carcinomatosis (PC) from colorectal cancer (CRC) has poor survival. Multi-modal treatment including systemic chemotherapy, cytoreductive surgery (CRS), and hyperthermic intraperitoneal chemotherapy (HIPEC) can be used in selected patients with curative intent. The majority published works consider PC of CRC origin as a homogenous disease. Aim of this study is to stress the different biological behaviors and survival of PC according to colonic or rectal origin. METHODS: Data of CRS and HIPEC procedures for PC of CRC origin performed at MD Anderson Cancer Center-Madrid (Spain) have been collected, dividing patients into two groups according to colonic or rectal PC. Clinical, operatory, and postoperatory variables of the two groups have been analyzed to compare survival-related rates and PC origin. RESULTS: In the years 2004-2015, 114 procedures of CRS followed by HIPEC for peritoneal metastasis of different origin have been performed; of these, 36 procedures were for colorectal PC (31 patients in colonic and 5 in rectal group). Two groups are homogenous after analysis of clinical, operatory, and follow-up data. Median survival (OS) is significantly higher in colonic compared to rectal group (47.83 vs. 22.0 months, p 0.008). 3- and 5-year survival rate is 74 and 50% in colonic group vs. 20 and 0% in rectal group. CONCLUSION: Rectal origin PC has a more aggressive behavior compared to colonic origin, reflecting in a worst prognosis of patients affected by rectal origin PC. According to our data and literature, indications of multi-modal treatment including CRS and HIPEC should be more restrictive for rectal cancer PC. Authors should differentiate colonic and rectal origin of PC when reporting cases in the literature.
Authors: J Esquivel; R Sticca; P Sugarbaker; E Levine; T D Yan; R Alexander; D Baratti; D Bartlett; R Barone; P Barrios; S Bieligk; P Bretcha-Boix; C K Chang; F Chu; Q Chu; S Daniel; E de Bree; M Deraco; L Dominguez-Parra; D Elias; R Flynn; J Foster; A Garofalo; F N Gilly; O Glehen; A Gomez-Portilla; L Gonzalez-Bayon; S Gonzalez-Moreno; M Goodman; V Gushchin; N Hanna; J Hartmann; L Harrison; R Hoefer; J Kane; D Kecmanovic; S Kelley; J Kuhn; J Lamont; J Lange; B Li; B Loggie; H Mahteme; G Mann; R Martin; R A Misih; B Moran; D Morris; L Onate-Ocana; N Petrelli; G Philippe; J Pingpank; A Pitroff; P Piso; M Quinones; L Riley; L Rutstein; S Saha; S Alrawi; A Sardi; S Schneebaum; P Shen; D Shibata; J Spellman; A Stojadinovic; J Stewart; J Torres-Melero; T Tuttle; V Verwaal; J Villar; N Wilkinson; R Younan; H Zeh; F Zoetmulder; G Sebbag Journal: Ann Surg Oncol Date: 2006-10-28 Impact factor: 5.344
Authors: Jan Franko; Zuhaib Ibrahim; Niraj J Gusani; Matthew P Holtzman; David L Bartlett; Herbert J Zeh Journal: Cancer Date: 2010-08-15 Impact factor: 6.860
Authors: Konstantinos I Votanopoulos; Katrina Swett; Aaron U Blackham; Chukwuemeka Ihemelandu; Perry Shen; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2013-03-02 Impact factor: 5.344
Authors: Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Fernando Pereira; Angel Serrano; Israel Manzanedo; Estibalitz Pérez-Viejo; Santiago González-Moreno; Luis González-Bayón; Alvaro Arjona-Sánchez; Juan Torres; Isabel Ramos; Maria E Barrios; Pedro Cascales; Rafael Morales; Enrique Boldó; Alfonso García-Fadrique; Xabier Arteaga; Alberto Gutierrez-Calvo; Susana Sánchez-García; Enrique Asensio; Cesar P Ramírez; Manuel Artiles; Javier Vaqué; Pedro A Parra; Pedro Villarejo; Cristóbal Muñoz-Casares; Estrella Turienzo; Alicia Calero; Isabel Jaén Torrejimeno; Isabel Prieto; Julio Galindo; Vicente Borrego; Manuel E Marcello; Cristina Rihuete; Joaquin Carrasco; Luis Gomez-Quiles Journal: BMC Cancer Date: 2022-05-12 Impact factor: 4.638